GlaxoSmithKline: Mepolizumab Meets Major Targets in Phase III Study
November 23 2016 - 02:56AM
Dow Jones News
By Ian Walker
LONDON--Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said
Wednesday a phase III study of mepolizumab has met all major
targets in patients with eosinophilic granulomatosis with
polyangiitis, a rare disease characterized by inflammation in the
walls of small blood vessels.
The key goal of treatment is to induce and maintain remission
while reducing the use of corticosteroids and other
immunosuppressive therapies, Glaxo said.
It plans to use the results to support regulatory applications,
which are expected in 2017.
Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
November 23, 2016 02:41 ET (07:41 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024